The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

StocksUpdated•Originally published 4 May 2026•Updated 4 May 2026•

1 min read

Clene to Seek Accelerated FDA Approval for ALS Treatment Following Positive Meeting

Key Facts

1The FDA stated that proposed data may support the submission and review of a New Drug Application (NDA) under the accelerated approval pathway.

2Clene expects to submit an NDA for CNM-Au8 to the FDA in the third quarter of 2026.

3The FDA acknowledged that neurofilament light (NfL) could potentially serve as a reasonably likely surrogate endpoint.

Clene Inc. (CLNN) has announced its intention to pursue an accelerated approval pathway for its ALS drug candidate, CNM-Au8, following a productive meeting with the FDA. The regulator indicated that the proposed data package may support an NDA submission, acknowledging neurofilament light (NfL) levels as a likely surrogate endpoint. Market reaction was notably positive, with CLNN stock jumping 6.68% during Monday's trading session following the announcement. Clene currently expects to submit the formal NDA in the third quarter of 2026. This regulatory progress marks a significant milestone for the company in addressing high unmet medical needs. While the filing date remains distant, the alignment with FDA guidance provides a clearer roadmap for commercialization.

about 1 month ago

Version History

Version 1about 1 month ago

What changed: Added specific market reaction with a 6.68% stock jump and included the official ticker symbol CLNN.